2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-149169
    Phevamine A 2280874-34-0 98%
    Phevamine A is a small molecule bacterial phytotoxin that can be isolated from Pseudomonas syringae. Phevamine promotes bacterial growth by suppressing plant immune responses.
    Phevamine A
  • HY-149200
    Lysine-methotrexate 80407-56-3 98%
    Lysine-methotrexate, an analogue of Methotrexate (HY-14519), is a dihydrofolate reductase (DHFR) inhibitor.
    Lysine-methotrexate
  • HY-149205
    CXJ-2 2919976-92-2 98%
    CXJ-2 is a cyclic peptide, and exhibits moderate affinity toward elastin derived peptides (EDPs). CXJ-2 exhibits potent activities to inhibit the PI3K/ERK pathway and decrease hepatic stellate cell proliferation and migration. CXJ-2 possesses potent antifibrotic efficacy.
    CXJ-2
  • HY-149218
    THR-β agonist 6 2791290-58-7 98%
    THR-β agonist 6 is an orally active, selective thyroid hormone receptor β (THR-β) agonist with EC50s of 0.03 μM and 0.22 μM for THR-β and THR-α, respectively. THR-β agonist 6 exhibits an xcellent liver-to-serum ratio of 93:1 in mice. THR-β agonist 6 has the potential for nonalcoholic steatohepatitis (NASH) research.
    THR-β agonist 6
  • HY-149235
    PI3Kδ-IN-12 98%
    PI3Kδ-IN-12 (compound 13) is a PI3Kδ inhibitor (pIC50 = 5.8), with pKi values of 8.0/6.5/6.4/6.7 for PI3Kδ/γ/β/α, respectively. PI3Kδ-IN-12 can be used in the study of chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
    PI3Kδ-IN-12
  • HY-149245
    Keap1-Nrf2-IN-15 2456295-45-5 98%
    Keap1-Nrf2-IN-15 (Compound 24a) is a potent Keap1-Nrf2 protein-protein interaction inhibitor with IC50s of 77 nM and 2.5 nM in FP assay and TR-FRET assay, respectively.
    Keap1-Nrf2-IN-15
  • HY-149246
    Aβ-IN-6 3043752-01-5 98%
    Aβ-IN-6 reduces pro-inflammatory cytokine release from microglia cells. Aβ-IN-6 significantly induces Nrf2 nuclear translocation and hamperes Aβ oligomers formation. Aβ-IN-6 exerts a consistent neuroprotective effect by modulating the redox-sensitive signalling pathways in vivo oxidative stress model. Aβ-IN-6 is an orally active and has antiinflammatory, Antioxidant and Anti-oligomeric activity. Aβ-IN-6 has the potential for Alzheimer's disease (AD) research.
    Aβ-IN-6
  • HY-149248
    NF-κB-IN-8 2924565-59-1 98%
    NF-κB-IN-8 competitively antagonizes LPS binding to MD-2. NF-κB-IN-8 reduces the expression of inflammatory factors by binding to MD-2. NF-κB-IN-8 also inhibits ALP activity. NF-κB-IN-8 can be used for the research of inflammation such as acute lung injury (ALI).
    NF-κB-IN-8
  • HY-149269
    COX-2-IN-30 1160498-08-7 98%
    COX-2-IN-30 is a benzenesulfonamide derivative, as well as an orally active and dual inhibitor of COX (IC50=49 nM for COX-2, 10.4 μM for COX-1) and 5-LOX (IC50=2.4 μM). COX-2-IN-30 also inhibits transmembrane hCA IX and hCA XII isoform with nanomolar calss Ki values. COX-2-IN-30 exhibits analgesic, anti-inflammatory, and ulcerogenic activities, and does not show acute gastric effect.
    COX-2-IN-30
  • HY-149270
    COX-2-IN-31 3039955-76-2 98%
    COX-2-IN-31 (compound 7b) is an orally active and dual inhibitor of COX-2 (IC50=60 nM) and 5-LOX (IC50=1.9 μM). COX-2-IN-31 also inhibits transmembrane hCA IX(Ki=48.9 nM) and hCA XII(Ki=5.8 nM) activity. COX-2-IN-31 exhibits anti-inflammatory and analgesic activity.
    COX-2-IN-31
  • HY-149296
    JAK1-IN-12 2945204-95-3 98%
    JAK1-IN-12 is a selective inhibitor of JAK1, with IC50 of 0.0246 μM. And IC50s of 0.423 μM, 0.410 μM and 1.12 μM for JAK2, JAK3 and TYK2. JAK1-IN-12 promotes hair growth in mice. JAK1-IN-12 can be used for research of immune and inflammatory diseases.
    JAK1-IN-12
  • HY-149299
    PYZ18 1447578-01-9 98%
    PYZ18 is a selective COX-2 inhibitor with an IC50 of 7.07 μM. PYZ18 is the best lead compound for COX-2 inhibitors. PYZ18 has anti-inflammatory and other biological properties.
    PYZ18
  • HY-14930R
    Mirodenafil (Standard) 862189-95-5 98%
    Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
    Mirodenafil (Standard)
  • HY-14930S
    Mirodenafil-d7 1329651-11-7 98%
    Mirodenafil-d7 (SK3530-d7) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
    Mirodenafil-d7
  • HY-149331
    TNF-α-IN-11 2945197-77-1 98%
    TNF-α-IN-11 (Compound 10) is a TNF-α inhibitor with a KD value of 12.06 μM. TNF-α-IN-11 binds to TNF-α and blocks the activation of TNF-α-trigged caspase and NF-κB signaling pathway. TNF-α-IN-11 inhibits the phosphorylation of IκBα, as well as the nuclear translocation of NF κB p65. TNF-α-IN-11 can be used for research of TNF-α-mediated autoimmune diseases.
    TNF-α-IN-11
  • HY-149345
    IRAK4-IN-24 2952533-54-7 98%
    IRAK4-IN-24 (compound 16) is a potent IRAK4 inhibitor, with high clearance (Cl) and poor oral bioavailability. IRAK4-IN-24 can be used for research in inflammatory and autoimmune disorders.
    IRAK4-IN-24
  • HY-149355
    COX-2-IN-33 3049405-60-6 98%
    COX-2-IN-33 (compound 5f) is a COX-2 inhibitor (IC50=45.5 nM), as well as a potential anti-inflammatory agent. COX-2-IN-33 inhibits in vivo pro-inflammatory cytokine production and keep gastric safety.
    COX-2-IN-33
  • HY-149365
    SIKs-IN-1 2927557-06-8 98%
    SIKs-IN-1 (compound 8h), a pyrimidine-5-carboxamide derivative, is a Salt-inducible kinases (SIKs) inhibitor. SIKs regulates the transformation of M1/M2 macrophages, involving in inflammation process. SIKs-IN-1 inhibits SIK activity, up-regulates anti-inflammatory cytokine IL-10, but down-regulates pro-inflammatory cytokine IL-12. SIKs-IN-1 shows excellent anti-inflammatory effects in a DSS-induced colitis model.
    SIKs-IN-1
  • HY-149386
    D3R/MOR antagonist 1 3033883-15-4 98%
    D3R/MOR antagonist 1 (Compound 114) is a D3R/MOR antagonist (Ki: 46.5 nM and 691 nM respectively). D3R/MOR antagonist 1 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism.
    D3R/MOR antagonist 1
  • HY-149387
    D3R/MOR antagonist 2 3033883-17-6 98%
    D3R/MOR antagonist 2 (Compound 121) is a D3R/MOR antagonist (Ki: 361 nM and 85.2 nM respectively). D3R/MOR antagonist 2 has the potential to produce analgesic effects through MOR partial agonism, reduce opioid-misuse liability via D3R antagonism.
    D3R/MOR antagonist 2
Cat. No. Product Name / Synonyms Application Reactivity